OTLK Relative Valuation
OTLK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OTLK is overvalued; if below, it's undervalued.
Historical Valuation
Outlook Therapeutics Inc (OTLK) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.72 is considered Undervalued compared with the five-year average of -4.20. The fair price of Outlook Therapeutics Inc (OTLK) is between 1.87 to 2.63 according to relative valuation methord. Compared to the current price of 0.53 USD , Outlook Therapeutics Inc is Undervalued By 71.7%.
Relative Value
Fair Zone
1.87-2.63
Current Price：0.53
71.7%
Undervalued
-0.89
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Outlook Therapeutics Inc. (OTLK) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-1.62
EV/EBIT
Outlook Therapeutics Inc. (OTLK) has a current EV/EBIT of -1.62. The 5-year average EV/EBIT is -4.03. The thresholds are as follows: Strongly Undervalued below -8.70, Undervalued between -8.70 and -6.36, Fairly Valued between -1.70 and -6.36, Overvalued between -1.70 and 0.64, and Strongly Overvalued above 0.64. The current Forward EV/EBIT of -1.62 falls within the Overvalued range.
1.72
PS
Outlook Therapeutics Inc. (OTLK) has a current PS of 1.72. The 5-year average PS is 273.89. The thresholds are as follows: Strongly Undervalued below -651.33, Undervalued between -651.33 and -188.72, Fairly Valued between 736.50 and -188.72, Overvalued between 736.50 and 1199.11, and Strongly Overvalued above 1199.11. The current Forward PS of 1.72 falls within the Historic Trend Line -Fairly Valued range.
-0.77
P/OCF
Outlook Therapeutics Inc. (OTLK) has a current P/OCF of -0.77. The 5-year average P/OCF is -4.83. The thresholds are as follows: Strongly Undervalued below -12.36, Undervalued between -12.36 and -8.60, Fairly Valued between -1.06 and -8.60, Overvalued between -1.06 and 2.71, and Strongly Overvalued above 2.71. The current Forward P/OCF of -0.77 falls within the Overvalued range.
-0.50
P/FCF
Outlook Therapeutics Inc. (OTLK) has a current P/FCF of -0.50. The 5-year average P/FCF is -1.77. The thresholds are as follows: Strongly Undervalued below -7.25, Undervalued between -7.25 and -4.51, Fairly Valued between 0.97 and -4.51, Overvalued between 0.97 and 3.71, and Strongly Overvalued above 3.71. The current Forward P/FCF of -0.50 falls within the Historic Trend Line -Fairly Valued range.
Outlook Therapeutics Inc (OTLK) has a current Price-to-Book (P/B) ratio of -1.10. Compared to its 3-year average P/B ratio of -2.27 , the current P/B ratio is approximately -51.41% higher. Relative to its 5-year average P/B ratio of 6.75, the current P/B ratio is about -116.36% higher. Outlook Therapeutics Inc (OTLK) has a Forward Free Cash Flow (FCF) yield of approximately -122.48%. Compared to its 3-year average FCF yield of -60.57%, the current FCF yield is approximately 102.22% lower. Relative to its 5-year average FCF yield of -42.83% , the current FCF yield is about 185.98% lower.
-1.10
P/B
Median3y
-2.27
Median5y
6.75
-122.48
FCF Yield
Median3y
-60.57
Median5y
-42.83
Competitors Valuation Multiple
The average P/S ratio for OTLK's competitors is 18.92, providing a benchmark for relative valuation. Outlook Therapeutics Inc Corp (OTLK) exhibits a P/S ratio of 1.72, which is -90.91% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of OTLK increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of OTLK in the past 1 year is driven by Unknown.
People Also Watch
AP
Ampco-Pittsburgh Corp
5.51USD
7.20%
SPRU
Spruce Power Holding Corp
5.07USD
-0.20%
PVL
Permianville Royalty Trust
1.87USD
0.54%
OVID
Ovid Therapeutics Inc
1.745USD
-0.85%
MAIA
Maia Biotechnology Inc
1.54USD
0.65%
GROV
Grove Collaborative Holdings Inc
1.23USD
1.65%
XLO
Xilio Therapeutics Inc
0.7098USD
2.16%
FTCI
FTC Solar Inc
12.115USD
1.47%
Frequently Asked Questions
Is Outlook Therapeutics Inc (OTLK) currently overvalued or undervalued?
Outlook Therapeutics Inc (OTLK) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.72 is considered Undervalued compared with the five-year average of -4.20. The fair price of Outlook Therapeutics Inc (OTLK) is between 1.87 to 2.63 according to relative valuation methord. Compared to the current price of 0.53 USD , Outlook Therapeutics Inc is Undervalued By 71.70% .
What is Outlook Therapeutics Inc (OTLK) fair value?
OTLK's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Outlook Therapeutics Inc (OTLK) is between 1.87 to 2.63 according to relative valuation methord.
How does OTLK's valuation metrics compare to the industry average?
The average P/S ratio for OTLK's competitors is 18.92, providing a benchmark for relative valuation. Outlook Therapeutics Inc Corp (OTLK) exhibits a P/S ratio of 1.72, which is -90.91% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Outlook Therapeutics Inc (OTLK) as of Jan 07 2026?
As of Jan 07 2026, Outlook Therapeutics Inc (OTLK) has a P/B ratio of -1.10. This indicates that the market values OTLK at -1.10 times its book value.
What is the current FCF Yield for Outlook Therapeutics Inc (OTLK) as of Jan 07 2026?
As of Jan 07 2026, Outlook Therapeutics Inc (OTLK) has a FCF Yield of -122.48%. This means that for every dollar of Outlook Therapeutics Inc’s market capitalization, the company generates -122.48 cents in free cash flow.
What is the current Forward P/E ratio for Outlook Therapeutics Inc (OTLK) as of Jan 07 2026?
As of Jan 07 2026, Outlook Therapeutics Inc (OTLK) has a Forward P/E ratio of -0.89. This means the market is willing to pay $-0.89 for every dollar of Outlook Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Outlook Therapeutics Inc (OTLK) as of Jan 07 2026?
As of Jan 07 2026, Outlook Therapeutics Inc (OTLK) has a Forward P/S ratio of 1.72. This means the market is valuing OTLK at $1.72 for every dollar of expected revenue over the next 12 months.